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The aim of this paper was to investigate differences in brain structure volumes between 
schizophrenia and affective psychoses, and whether cumulative lifetime antipsychotic or 
benzodiazepine doses relate to brain morphology in these groups. We conducted two systematic 
reviews on topic and investigated 44 schizophrenia cases and 24 with affective psychoses from the 
Northern Finland Birth Cohort 1966. The association between lifetime antipsychotic and 
benzodiazepine dose and brain MRI scans at the age of 43 was investigated using linear regression. 
Intracranial volume, sex, illness severity, and antipsychotic/benzodiazepine doses were used as 
covariates. There were no differences between the groups in brain structure volumes. In 
schizophrenia, after adjusting for benzodiazepine dose and symptoms, a negative association 
between lifetime antipsychotic dose and the nucleus accumbens (b=-0.397, p=0.024) remained. In 
affective psychoses, higher lifetime benzodiazepine dose associated with larger volumes of total 
gray matter (b=0.301, p= 0.020), cerebral gray matter (b=0.291, p= 0.025), and thalamus (b=0.352, 
p= 0.044) after controlling for antipsychotic use and symptoms. It seems that in addition to 
antipsychotics, also severity of symptoms, benzodiazepine dose and duration of illness associates to 
brain structure volumes. These results suggest, that benzodiazepine effect should be investigated 
independently and not only as a confounder.  
Key words: schizophrenia, affective psychoses, brain, MRI, psychopharmacology. 
1. Introduction  
Though affective psychoses are common, they are much less investigated than schizophrenia. They 
have been considered distinct disease entities with differing aetiology of schizophrenia, though 
these psychotic disorders also share some similarities. Structural brain changes are found in both 
individuals with schizophrenia (Hulshoff Pol and Kahn 2008; Olabi et al., 2011; Vita et al., 2012) 
and affective psychoses (Bora et al., 2008; Busatto 2013) when compared to controls. In 
schizophrenia these changes include both gray and white matter reductions (Olabi et al., 2011), 
especially in gray matter in the frontal and temporal lobes, hippocampus/amygdala, thalamus and 
insula (Shepherd et al., 2012). Though similarities can be found in the brain structures in psychotic 
bipolar disorder compared to schizophrenia, gray matter abnormalities and hippocampal volume 
reductions are more common in schizophrenia (Bora et al., 2008). Likewise, there are abnormalities 
in brain structures in psychotic depression compared to non-psychotic depression, but less 
prominently than in schizophrenia (Busatto 2013).  
The current key treatment of psychosis, regardless of its aetiology or the underlying illness, is 
antipsychotic medication. Suggested harmful effects of high dose long-term antipsychotic treatment 
on brain structure volumes in psychoses are a debated issue with no consensus (Fusar-Poli et al., 
2013; Huhtaniska et al., 2017a). Gray matter reductions have been detected also in populations at 
high risk for psychosis (Wood et al., 2008) and drug naïve first episode schizophrenia patients 
(Leung et al., 2011), which most likely reflects the pathological process leading to illness onset. 
However, there are some evidence from animal studies that antipsychotic medications affect brain 
structures even when illness-related factors are not present (Dorph-Petersen et al., 2005; Vernon et 
al., 2014, 2011). In addition, as the altered morphological findings are not present in all psychotic 
individuals across diagnoses, it seems that in addition to neurodevelopmental disturbances, also 
environmental factors like medication might additionally contribute to their origin. 
According to our previous meta-analysis on long-term antipsychotic effects on brain structures, 
higher antipsychotic doses associated with decrease in parietal lobe volume and increase in basal 
ganglia volume (Huhtaniska et al., 2017a). Many previous reviews have included both longitudinal 
and cross sectional studies. In data supplement table 1 we present previous systematic reviews on 
cross-sectional studies on antipsychotic medication effects on brain structures in schizophrenia. 
Based on these, higher doses of antipsychotics have been associated with lower total brain and 
midbrain volumes, higher doses of typical antipsychotics to lower gray matter, larger basal ganglia, 
and larger thalamic volumes, and higher doses of atypical antipsychotics to a larger volume of 
caudate nucleus, thalamus, and hippocampus (Haijma et al., 2013; Navari and Dazzan 2009; Scherk 
and Falkai 2006; Smieskova et al., 2009).  
In addition to antipsychotics, individuals with psychosis are often medicated with other psychiatric 
medications, such as benzodiazepines. When studying medication effects in a non-controlled 
population, it is important to take into account the possible confounding effects of other 
medications. To our knowledge, the effect of benzodiazepine use on brain structures has not been 
studied before in psychoses with the exception of our previous longitudinal study of the Northern 
Finland Birth Cohort 1966 (NFBC1966) in a smaller sample (Huhtaniska et al., 2017b). Previously 
benzodiazepine use has been associated with decline in cognition (Baandrup et al., 2017; Fond et 
al., 2017) and increased mortality (Fontanella et al., 2016) in schizophrenia, and decreased brain 
plasticity in mice (Curto et al., 2016; Huopaniemi et al., 2004). Therefore, it is interesting to 
examine, whether there are also effects on brain structures on a macroscopic level. 
The naturalistic design  of our NFBC1966 data offers an opportunity to study medication effects on 
brain structures in a population based birth cohort setting during midlife. We are able to analyze 
data of individuals with psychosis several years after illness onset and several years of treatment. 
We have previously published longitudinal findings from  NFBC1966 follow-up study performed at 
ages 34 and 43 years for schizophrenia subjects. In these studies, higher doses of antipsychotic 
medication over the follow-up was associated with a larger total brain volume loss (Veijola et al., 
2014), a degree of periventricular brain reduction at the fourth ventricular edge (Guo et al., 2015), 
and an increase in lateral ventricles after adjusting for symptom severity (Huhtaniska et al., 2017b). 
Higher benzodiazepine doses during the follow-up was associated with a volume decrease in the 
caudate nucleus even after controlling for antipsychotic use and illness severity (Huhtaniska et al., 
2017b).  
In this study, in addition to analysing associations between lifetime antipsychotic and 
benzodiazepine doses and brain structures in schizophrenia at early midlife, we wanted to 
investigate and compare whether these medications would also associate with brain structures in a 
group of individuals with affective psychoses, a group that has been studied considerably less than 
schizophrenia. First, we systematically reviewed earlier literature on differences in brain 
morphology between schizophrenia and affective psychoses and findings regarding antipsychotic or 
benzodiazepine effects on brain structures in affective psychoses.  Then, our main aim was to 
analyse in a general population-based sample at the age of 43 years, whether there are differences in 
the brain volumes between schizophrenia and affective psychoses (schizoaffective disorder, 
psychotic depression or psychotic bipolar disorder) and whether lifetime antipsychotic or 
benzodiazepine doses associate with brain structure volumes when controlling for illness severity 
measures. The hypotheses were that 1) individuals with schizophrenia would show larger 
ventricular size or smaller volumes of brain structures than individuals with affective psychoses, 2) 
larger lifetime doses of antipsychotics and benzodiazepines would associate with either larger 
ventricular size or smaller volumes in brain structures, and 3) the effect of medication would not 
differ between the groups.  
2. Methods  
2.1 Systematic reviews 
To systematically review findings on structural differences in the brain between schizophrenia and 
affective psychoses, a literature search was conducted the 4th of May 2017 from the database of 
PubMed. We used the search terms: psychotic and (bipolar or depressive or depression) and MRI 
and brain, and the search was directed to human studies only. Inclusion criteria were cross-sectional 
design and brain volume comparisons were made between any affective psychosis group and 
schizophrenia. Only studies comparing two groups with a history of psychosis were included. 
To examine previous findings regarding antipsychotic and benzodiazepine use and brain structures 
in affective psychoses, a literature search was conducted the 4th of May 2017 from the database of 
PubMed. We used the search terms: psychotic and (bipolar or depressive or depression or affective) 
and (antipsychotic or benzodiazepine) and MRI and brain and (structure or structural or 
morphometry), and the search was directed to human studies only. In addition, we screened 
previous reviews on topic, references of included studies and all the included studies from the 
previously described search regarding differences between brain structures in schizophrenia and 
affective psychoses. Inclusion criteria was that the association between antipsychotic or 
benzodiazepine medication and brain structures was examined in any sample of affective psychosis. 
2.2 Sample of NFBC1966 
The participants of this study were members of the Northern Finland Birth Cohort 1966 
(NFBC1966), which is an unselected, general population birth cohort identified during mid-
pregnancy based on an expected delivery date during 1966 in the provinces of Lapland and Oulu, 
Finland. The cohort has been described in more detail in previous publications (Husa et al., 2017; 
Nykänen et al., 2016).  Permission to gather data was obtained from the Ministry of Social and 
Health Affairs and the study design was approved by the Ethical Committee of the Northern 
Ostrobothnia Hospital District.  
This study is based on 68 individuals with psychosis from the NFBC1966, who participated in the 
brain MRI scan, psychiatric interviews and examinations in 2008-2011, at an average age of 43 
years (SD 0.8), and had adequate structural MRI scans. Diagnoses were based on information from 
national registers, hospital notes and SCID-I interview (First et al., 2002) performed during the 
study at the age 43 years (hereafter “43-year study”). The sample included 44 cases with 
schizophrenia (including 2 cases with schizophreniform disorder), and 24 cases with affective 
psychosis (including 5 cases with schizoaffective disorder, 6 with bipolar psychosis, and 13 with 
psychotic depression). Written informed consent was obtained from all participants and the 
participants have the possibility to deny the use of their data at any time. 
2.2.1 Data on use of psychiatric medication 
Information on lifetime use of psychiatric medications, until the day the person was examined in the 
43-year study, was gathered by a careful review of individual hospital, outpatient and health centre 
notes of all cases from everywhere in Finland. This procedure is described in more detail in 
previous publications from the NFBC1966 (Husa et al., 2014; Moilanen et al., 2015). Current and 
earlier use of psychiatric medications and their doses were also ascertained in the interview at 43-
year study by asking about the use of psychiatric medications during the previous 3 months and as 
far as the subjects could remember. 
All medical records were reviewed to record the name of the drug, dose and period the medication 
had been used. Drugs were categorized by using the Anatomical Therapeutic Chemical (ATC) 
classification system (WHO 2010). Antipsychotics included classes N05A (antipsychotics) and 
N06CA01 (combination medicine including perphenazine). Benzodiazepines included classes 
N05BA (anxiolytics, benzodiazepine derivatives), N05CD (hypnotics and sedatives, 
benzodiazepine derivatives), and N05CF (hypnotics and sedatives, benzodiazepine-related drugs). 
The information was used to calculate the cumulative dose of lifetime medication in defined daily 
doses (DDD) and these were then expressed as dose-years. One DDD year (DDDy) is equivalent to 
using one DDD daily for a year.  
2.2.3 Covariates 
As a marker of illness severity, we used Positive and Negative Syndrome Scale (PANSS) (Kay et 
al., 1987), which was assessed at the 43-year study using a specific interview. The age at onset of 
the illness was ascertained from medical records and it was defined as the age of first evident 
psychotic symptoms. Due to the birth cohort design, age of illness onset reflects also duration of 
illness. Also sex and intracranial volume (ICV) were used as covariates.  
2.2.4 Imaging data 
The participants were scanned with the same 1.5 T GE Signa scanner (General Electric, Milwaukee, 
Wisconsin) at the Oulu University Hospital at the 43-year study. T1 weighted images were acquired 
with a 3D fast spoiled gradient echo (FSPGR) sequence (slice thickness = 1 mm; in-plane resolution 
matrix size 256x256; voxel size 1 mm
3
; repetition time 12.576 ms; echo time 5.3 ms; flip angle 
=20º). 
To extract the brain structure volumes from the MRI images we used an online automated MRI 
brain volumetry system volBrain (http://volbrain.upv.es/) (Manjón and Coupé 2016). Based on 
previously reported reliability measures (Huhtaniska et al., 2017b) and previous brain imaging 
findings in psychoses, we selected 10 brain areas to be examined: total brain, total gray matter 
(GM), cerebrum, cerebral GM, lateral ventricles, caudate, putamen, thalamus, hippocampus, 
accumbens). Details on the reliability measures and image processing pipeline are described in our 
previous publication (Huhtaniska et al., 2017b) and briefly in supplementary material. 
2.2.5 Statistical analyses  
Independent samples t-test was used to assess the differences between the background variables of 
the groups. Differences between brain areas of subjects with schizophrenia and affective psychoses 
and associations between lifetime and medication doses and brain areas were analysed in both 
groups. A logarithmic transformation was applied to medication data because of the skewness of the 
variables and these were used as continuous variables in analyses. All confounders were analysed as 
continuous variables. 
We used several models to investigate the associations between lifetime medication doses and brain 
structures in both groups. All analyses were made using linear regression with sex and intracranial 
volume (ICV) as covariates. The medication analyses were additionally adjusted for PANSS total 
score and onset age. Benzodiazepine DDDy were added as a covariate in analyses of antipsychotic 
DDDy, and vice versa. In addition, we analysed the group × medication interactions in models with 
group + group × medication interaction + medication dose (antipsychotic or benzodiazepine) + ICV 
+ sex. No corrections for multiple comparisons were made due to the possibility of overcorrecting 
the results. The analyses were performed using IBM SPSS Statistics version 23 using p<0.05 as a 
limit for statistical significance. 
3. Results 
3.1 Systematic reviews  
3.1.1. Differences in brain structures between schizophrenia and affective psychoses 
The search located 291 studies and after abstract and title review 94 articles were evaluated in 
detail. The final number of included studies was 30. The data collection in presented in data 
supplement figure 1 and detailed information on included studies are presented in data supplement 
table 2. 
Of the found 30 studies, 15 examined differences between schizophrenia and psychotic bipolar 
disorder cases. Only six studies investigated differences between mixed mood disorder group and 
schizophrenia and only two studies differences between psychotic depression and schizophrenia. A 
summary of the findings of the review is presented in Table 1. In the studies with statistically 
significant findings, the cortical volumes were smaller in the schizophrenia group compared to 
affective psychoses groups, and the only findings with larger volumes in schizophrenia were found 
in putamen, caudate and globus pallidus when compared to psychotic bipolar disorder (Mamah et 
al., 2016; Rimol et al., 2010). Regarding lateral ventricles, the size was larger in schizophrenia than 
in psychotic bipolar disorder (McDonald et al., 2006), but larger in psychotic depression than in 
schizophrenia (Salokangas et al., 2002). Of the found 30 studies, 9 did not find any differences 
between these groups in their regions of interest (Cui et al., 2001; Janssen et al., 2014; Koo et al., 
2008; Morgan et al., 2007; Radonic et al., 2008; Reite et al., 2010; Rosa et al., 2010; Rosa et al., 
2015; Strasser et al., 2004).  
Table 1. Summary of the findings in schizophrenia based on the systematic review of differences in brain 




Statistically significant findings between schizophrenia and psychotic bipolar disorder:  
- Smaller volumes in cerebellum  
- Gray matter deficits in cerebellum 
Ivleva et al., 2012; Ivleva et al., 2013 
Nenadic et al., 2015b 
- Widespread cortical and subcortical gray matter volume 
reductions 
Brown et al., 2011; Ivleva et al., 2012; Ivleva et al., 2013; Mamah 
et al., 2016; McDonald et al., 2005; Nenadic et al., 2015a, 
2015b; Salokangas et al., 2002; Harvey et al., 1994 
- Smaller cerebral gray matter volume 
- Smaller total gray matter volume 
Harvey et al., 1994 
Mamah et al., 2016 
- Smaller gray matter volume in subgenual cortex Yüksel et al., 2012 
- Smaller hippocampal volumes Arnold et al., 2015; McDonald et al., 2006; Radonic et al., 2011; 
GM: Brown et al., 2011; Nenadic et al., 2015 
- Larger volume of putamen  
- Smaller volume of putamen  
Mamah et al., 2016; RImol et al., 2010 
Brown et al., 2011 
- Different shape of amygdala  
- Smaller amygdala 
- Smaller gray matter volume in amygdala 
Mahon et al., 2015 
Mahon et al., 2012 
Brown et al., 2011 
- Larger volumes of caudate and globus pallidus Mamah et al., 2016 
- Larger ventricle volumes Mc Donald et al., 2006 
 
  Statistically significant findings between schizophrenia and schizoaffective disorder  
- Smaller gray matter volumes in frontotemporal, cingulate, 
parietal and occipital cortices 
Ivleva et al., 2012 
 
Statistically significant findings between schizophrenia and psychotic depression  
- Smaller volume in left posterior subgenual cortex  Coryel et al., 2005  
- Smaller ventricular CSF volumes Salokangas et al., 2002 
 
Statistically significant findings between schizophrenia and combined affective psychoses group 
- Smaller total brain and total gray matter volumes El-Sayed et al., 2010 
- Smaller insular gray matter volume  Kasai et al., 2003 
- Higher rate of cavum septum pellucidum Jurjus et al., 1993 
 
No differences between schizophrenia and psychotic bipolar disorder 
- Gray matter VBM Cui et al., 2011 
- Lobar cortical thickness, surface are, gyrification index and 
sulcal width 
Janssen et al., 2014 
- Intracranial volume, white matter volume, nucleus accumbens 
and thalamic volumes 
Mamah et al., 2016 
- Cerebral volume Mc Donald et al., 2006 
- Temporal lobe volume and asymmetry Radonic et al., 2008 
- Superior temporal gyrus laminar thickness Ratnanather et al., 2013 
- Lateral ventricles Rosa et al., 2010 
- Cortical thickness, hippocampus, amygdala, thalamus, 
ventricles, nucleus accumbens, ventral diencephalon, cerebellar 
cortex or white matter, caudate, pallidum or brainstem 
Rimol et al., 2010 
- Left hippocampus, lateral ventricles Strasser et al., 2004 
 
No differences between schizophrenia and schizoaffective disorder 
- gray matter VBM Ivleva et al., 2013 
- Intracerebral volume, total brain volume, ventricular volume Reite et al., 2010 
- Temporal lobe volume and asymmetry Radonic et al., 2008 
 
No differences between schizophrenia and combined affective psychoses group 
- Frontal lobes, superior temporal cortices, hippocampus, insula, 
whole brain VBM 
Rosa et al., 2015 
- Temporal pole gray matter volume Kasai et al., 2003 
- VBM Morgan et al., 2007 
- Cingulate gyrus gray matter volumes in 3 anterior subregions 
and 1 posterior subregion 
Koo et al., 2008 
VBM= voxel-based morphometry 
*=smaller 
 
3.1.2 Associations between antipsychotic and benzodiazepine use in affective psychoses 
The search located 18 studies, of which 8 fulfilled our inclusion criteria. In addition, 63 full text 
articles from other sources were investigated. In total, 71 articles were assessed in detail, and 15 
studies were included in the systematic review. The data collection is described in data supplement 
figure 2 and detailed information on all included studies in data supplement table 3. 
Of the 15 included studies, the majority did not find associations between medication and brain 
structures. Only two studies found statistically significant associations: one found an association 
between antipsychotics and positive vertex displacement in right pallidum in psychotic bipolar 
disorder (Liberg et al., 2015), and another between longer duration of antipsychotic exposure and 
increased ventricular volumes in affective psychoses but not in schizophrenia (Morgan et al., 2007). 
A summary of the findings of the review is presented in Table 2. 





- Longer duration of antipsychotic exposure correlated with 
increased third ventricle and lateral ventricle volumes in affective 
psychoses group 
 
Morgan et al., 2007 
- Significant association between antipsychotics and positive 
vertex displacement in the right pallidum in psychotic bipolar 
disorder 
 
Liberg et al., 2015 
- No association between antipsychotic medication and 
investigated brain volumes 
Arnold et al., 2015; Giakoumatos et al., 2015; Ivleva et al., 2012; 
Ivleva et al., 2013; Janssen et al., 2014; Kasai et al., 2003; Koo 
et al., 2008; Mathew et al., 2014; Rimol et al., 2010; Rosa et al., 
2010; Strakowski et al., 1999; Woodward and Heckers 2015; 
Yüksel et al., 2012 
 
3.2 Characteristics of the sample  
The characteristics of the sample are described in Table 3. The schizophrenia group included more 
males (61%) than the affective psychoses group (29%). Only 10% of the schizophrenia group were 
married/cohabited compared to the 50% in affective psychoses group. The PANSS total and 
subscores were also higher in the schizophrenia group and fewer individuals were in remission 
(21%) than in the affective psychoses group (88%). The onset age was significantly lower in the 
schizophrenia group compared to the affective psychoses group. However, there were no significant 
differences in educational level or the number of people on disability pension between the groups. 
There were no statistically significant differences between brain volumes of the two groups in any 
studied brain areas, see data supplement table 4 for details. 
3.2.1 Characteristics of lifetime medication use 
The characteristics of medication use in the sample are presented in Table 4. In the schizophrenia 
group 42 (96%) individuals had used antipsychotics during lifetime, and the cumulative mean dose 
was 20.1 DDDy. Thirty-nine (88%) individuals had used typical and 35 (80%) individuals atypical 
antipsychotics. Thirty-three (75%) individuals had used benzodiazepines (mean dose 9.1 DDDy). 
Thirty-two (73%) individuals had used both antipsychotics and benzodiazepines. In the affective 
psychoses group 20 (83%) individuals had used antipsychotics (mean dose 4.7 DDDy). Fifteen 
(63%) individuals had used typical and 16 (67%) individuals atypical antipsychotics. Ten (41%) 
individuals had used benzodiazepines (mean dose 6.6 DDDy). Nine (38%) had used both 
benzodiazepines and antipsychotics.  All the used medications are listed in data supplement table 5. 
Many of the study subjects had used several different antipsychotics during their lifetime, especially 
those with schizophrenia. 
  





Gender* N (%)   
Male 27 (61) 7 (29)  
Age at the study moment, years (SD)   
Mean age, Range 43.1 (0.7), 41.8 – 44.5 43.6 (0.7), 41.9 – 44.7 
Marital status at the study moment * N (%)   
Married or cohabiting 10 (23) 12 (50) 
Single 34 (77) 12 (50) 
Educational level at the study moment N (%)    
Low 24 (55) 15 (63) 
Middle 10 (23) 6 (25) 
High 10 (23) 3 (13) 
Work status at the study moment N (%)   
Disability pension 26 (60) 12 (50) 
Employed 12 (27) 8 (33) 
Other
a 
5 (11) 3 (13) 
Current alcohol abuse N (%) 4 (9) 5 (21) 
Diagnosis N (%)   
Schizophrenia 42 (96)  
Schizophreniform disorder 2 (4)  
Schizoaffective disorder  5 (21) 
Psychotic bipolar disorder  6 (25) 
Psychotic depression  13 (54) 
Lifetime hospital treatment days   
Mean (SD) median, range 579 (899) 213, 1-5093 162 (122) 146, 2-399 
PANSS* mean (SD) median, range   
Total symptoms score 70 (27), 26, 30-130 43 (9.7), 11, 31-75 
Positive symptoms score 17 (8) 16, 6-32 9 (3) 9, 4-16 
Negative symptoms score 19 (10) 17, 8-43 12 (4) 10, 8-21 
Emotional symptoms score 18 (7) 16, 8-33 12 (3) 10, 8-19 
Excitement symptoms score 15 (5) 14, 8-29 10 (2) 10, 8-14 
Disorganized symptoms score 25 (12) 23, 10-59 16 (6) 14, 9-36 
Remission* N (%) 11 (25) 21 (88) 
Onset age* mean (SD), Range 25 (6.3), 16.7–42.0 32 (6.3), 21.4–41.2 
Current use of medication N (%),  
mean DDD (SD) 
  
Antipsychotics 35 (80), 203 (218) 17 (71), 280 (192) 
Benzodiazepines 20 (45), 33  (21) 5 (21), 28 (11) 
a= unemployed or not in working life due to other reasons than disability pension 
PANSS= Positive And Negative Syndrome Scale, DDD= defined daily dose. 
*=statistically significant differences between the groups. 
The cumulative number of hospital days since illness onset until the 43-years study was collected from the Care 
Register for Health Care. Remission was assessed using the remission criteria by Andreasen et al., (2005), and 
based on PANSS interview. The symptoms were only required not to be present during the period of one week before 
the assessment, and no duration criteria was used since PANSS was done only once.  
 
  
Table 4. Number of persons using antipsychotics and benzodiazepines during their lifetime and lifetime 
doses of medication.  
 Schizophrenia (N=44) 
N (%
a
), mean DDDy (SD) 
Affective psychoses (N=24) 
N(%
a
), mean DDDy (SD) 
Use of antipsychotics in DDDy    
Use of antipsychotics  
42 (96), 20.1 (20.5) 20 (83), 4.7 (5.2) 
Use of typical antipsychotics  
39 (88), 11.3 (14.9) 15 (63), 1.8 (2.7) 
Use of atypical antipsychotics  
35 (80), 11.5 (9.4) 16 (67), 4.2 (4.4) 
Use of benzodiazepines in DDDy   
Use of benzodiazepines  33 (75) 9.1 (10.5) 10 (41), 6.6 (8.0) 
Use of benzodiazepines only irregularly  5 (11) 2 (8) 
Use of both antipsychotics and benzodiazepines 32 (73), ap 23.5 (22.4), bzd 9.4 
(10.6) 
9 (38), ap 6.6 (6.9), bzd 7.1 (8.4) 
a= the percentage of cases that have had the medication at any point of their illness 
N= number of cases, SD= Standard Deviation, DDDy= dose years in defined daily dose, ap= antipsychotic, bzd= benzodiazepine. 
 
3.2.3 Association between lifetime cumulative antipsychotic doses and brain volumes  
In schizophrenia, higher cumulative lifetime antipsychotic doses were associated with brain 
volumes in several areas (see data supplement table 6 for details), and after adjusting the analyses 
for benzodiazepine use (see Table 5), the associations remained in total GM (b= -0.25, p= 0.017), 
cerebral GM (b= -0.25 p= 0.024), thalamus (b= -0.39 p= 0.014) and nucleus accumbens (b= -0.40, 
p= 0.014). After adding onset age to the model, the statistically significant associations still 
remained in total GM (b= -0.26, p= 0.025), cerebral GM (b= -0.29, p= 0.019), thalamus (b= -0.42, 
p=0.016), nucleus accumbens (b= -0.46, p= 0.011), and the lateral ventricles (b= 0.39, p= 0.046). 
When replacing onset age with PANSS total score as a marker of illness severity, only the 
association in nucleus accumbens remained (b= -0.38, p= 0.033) statistically significant, though the 
finding in thalamus almost reached significance as well (b= -0.34, p= 0.050). However, in the 
PANSS adjusted analyses, PANSS total score did not either associate to the structure volumes with 
the exception of lateral ventricles (b= 0.43, p= 0.018). The results of the analyses with both 
medication types are presented in Table 5 and the results of further adjusted analyses in Table 6. 
There were no associations between lifetime antipsychotic doses and volumes of brain structures in 
affective psychoses (Tables 5 and 6, data supplement table 6). 
3.2.4 Association between lifetime cumulative benzodiazepine dose and brain volumes  
In schizophrenia higher lifetime benzodiazepine doses associated with lower volumes of total brain 
(b= -0.23, p= 0.002) and cerebrum (b= -0.21, p= 0.006).  After adjusting the analysis for 
antipsychotic doses, no associations remained. When onset age was added to the model, there was 
again a significant association between higher benzodiazepine doses and lower volumes in total 
brain (b= -0.17, p= 0.044), but this association did not remain when adjusting for PANSS total 
score instead of onset age (Tables 5 and 6, data supplement table 6). 
In affective psychoses, higher lifetime doses of benzodiazepines were associated with larger 
volumes in total GM (b= 0.30, p= 0.020), cerebral GM (b= 0.29, p= 0.025) and thalamus (b= 0.35, 
p= 0.044) after adjusting the analyses for cumulative antipsychotic dose and PANSS total score 
(Tables 5 and 6, data supplement table 6). 
3.2.5 Interaction analyses  
There were no statistically significant associations between group × antipsychotic interaction and 




Table 5. Association between antipsychotic DDDy, benzodiazepine DDDy and brain volumes in the same 
model in schizophrenia cases and cases with affective psychoses. Sex and ICV as covariates. Statistically 
significant findings in bold. 
 
  Antipsychotic dose and benzodiazepine in the same model 
Brain area  Schizophrenia (N=44) Affective psychoses (N=24) 
  b p b p 
Total Brain 
ap -0.128  0.118 -0.398  0.695 
bzd -0.154  0.062 0.134  0.136 
Total GM 
ap -0.251  0.017 0.060  0.626 
bzd 0.028  0.786 0.325  0.014 
Cerebrum 
ap -0.134  0.125 -0.018  0.835 
bzd -0.138  0.115 0.160  0.072 
Cerebrum GM 
ap -0.247  0.024 0.084  0.482 
bzd 0.044  0.682 0.315  0.014 
Lateral ventricles 
ap 0.325  0.061 0.250  0.274 
bzd 0.064  0.699 -0.221  0.331 
Caudate  
ap 0.002  0.990 0.626  0.114 
bzd 0.121  0.471 0.217  0.184 
Putamen  
ap 0.169  0.282 0.069  0.711 
bzd 0.004  0.980 0.219  0.247 
Thalamus  
ap -0.387  0.014 -0.269  0.089 
bzd 0.005  0.971 0.361  0.026 
Hippocampus  
ap -0.255  0.113 -0.213  0.154 
bzd -0.077  0.627 0.299  0.051 
Accumbens  
ap -0.396  0.014 0.146  0.396 
bzd 0.134  0.390 -0.475  0.068 
ICV= intracranial volume, b= standardized beta, ap= antipsychotic, bzd= benzodiazepine.    
  
  
Table 6. Statistically significant associations between antipsychotic doses, benzodiazepine doses, total 
PANSS score or onset age and brain volumes in the same model in schizophrenia cases and cases with 




Antipsychotic dose, benzodiazepine dose and 
PANSS in the same model 
Antipsychotic dose, benzodiazepine dose 
and onset age in the same model 









Total Brain AP b=-0.078 p=0.387 b=-0.012 p= 0.910 b= -0.165 p= 0.070 b= -0.013 p=0.870 
 BZD b= -0.113 p= 0.204 b= 0.117 p= 0.200 b= -0.171 p= 0.044 b= 0.199 p= 0.030 
 PANSS/onset age b= -0.127 p= 0.163 b= -0.074p= 0.461 b= -0.082 p= 0.334 b= 0.188 p= 0.047 
Total GM AP b= -0.171 p= 0.120 b= 0.142 p= 0.312 b= -0.263 p=0.025 b= 0.076 p=0.537 
 BZD b= 0.079 p= 0.453 b= 0.301 p= 0.020 b= 0.022 p= 0.831 b= 0.375 p= 0.009 
 PANSS/onset age b=-0.202 p= 0.066 b= -0.194p= 0.153 b= -0.026 p= 0.808 b= 0.146 p= 0.291 
Cerebrum AP b= -0.073 p= 0.445 b= -0.005 p= 0.962 b= -0.183 p= 0.060 b= 0.001 p= 0.991 
 BZD b= -0.091 p= 0.329 b= 0.148 p= 0.105 b= -0.160 p= 0.075 b= 0.218 p= 0.018 
 PANSS/onset age b= -0.157 p= 0.104 b= -0.054p= 0.579 b= -0.107 p= 0.237 b= 0.168 p= 0.072 
Cerebrum GM AP b= -0.159 p= 0.157 b= 0.161 p= 0.261 b= -0.286 p=0.019 b= 0.094 p=0.440 
 BZD b= 0.097 p= 0.375 b= 0.291 p= 0.025 b= 0.027 p= 0.808 b= 0.347 p= 0.013 
 PANSS/onset age b= -0.221 p= 0.052 b= -0.170 p= 0.213 b= -0.085 p= 0.444 b= 0.094 p= 0.488 
Lateral ventricles AP b= 0.160 p= 0.363 b= 0.195 p= 0.479 b= 0.388 p= 0.046 b= 0.206 p= 0.349 
 BZD b= -0.060 p= 0.725 b=-0.174 p= 0.463 b= 0.069 p= 0.692 b= -0.358 p= 0.132 
 PANSS/onset age b= 0.432 p= 0.018 b= 0.225 p= 0.393 b= 0.137 p= 0.444 b= -0.396 p= 0.113 
Caudate  AP b= 0.031 p= 0.867 b= 0.296 p= 0.157 b= -0.078 p= 0.674 b= 0.299 p=0.057 
 BZD b= 0.157 p= 0.391 b= 0.205 p= 0.249 b= 0.086 p= 0.614 b= 0.333 p= 0.046 
 PANSS/onset age b= -0.062 p= 0.738 b= -0.067 p= 0.730 b= -0.175 p= 0.319 b= 0.337p= 0.053 
Putamen  AP b= 0.168 p= 0.324 b= 0.108 p= 0.627 b= 0.008 p=0.962 b= 0.058 p= 0.761 
 BZD b= -0.033 p= 0.840 b= 0.229 p= 0.237 b= -0.067 p= 0.662 b= 0.186 p= 0.366 
 PANSS/onset age b= -0.022 p= 0.894 b= -0.020 p= 0.926 b= -0.352 p= 0.028 b= -0.095 p= 0.656 
Thalamus  AP b= -0.336 p= 0.050 b= -0.261 p= 0.185 b= -0.421 p=0.016 b= -0.252 p= 0.115 
 BZD b= 0.043 p= 0.794 b= 0.352 p= 0.044 b= -0.011 p= 0.941 b= 0.414 p= 0.019 
 PANSS/onset age b= -0.111 p= 0.508 b= -0.043 p= 0.813 b= -0.085 p= 0.592 b= 0.154 p= 0.374 
Hippocampus  AP b= -0.232 p= 0.201 b=-0.121 p= 0.500 b=-0.317 p= 0.078 b= -0.196 p= 0.193 
 BZD b= -0.055 p= 0.755 b= 0.268 p= 0.093 b= -0.105 p= 0.523 b= 0.352 p= 0.035 
 PANSS/onset age b= -0.061 p= 0.734 b= -0.176 p= 0.306 b= -0.136 p= 0.416 b= 0.154 p=0.352 
Accumbens  AP b= -0.375 p= 0.033 b= 0.332 p= 0.066 b= -0.460 p=0.011 b=0.178 p= 0.289 
 BZD b= 0.132 p= 0.430 b= -0.397 p= 0.538 b= 0.106 p= 0.505 b= 0.108 p= 0.540 
 PANSS/onset age b= -0.048 p=0.777 b= -0.397 p= 0.024 b= -0.139 p= 0.393 b= 0.287 p= 0.130 
ICV= intracranial volume, b= standardized beta, ap= antipsychotic, bzd= benzodiazepine  
  
4. Discussion 
4.1 Main results 
We found no differences in brain structure volumes at the age of 43 years between the two 
diagnostic groups, even though onset age (which corresponds to duration of illness in this sample) 
and illness severity (PANSS total score) were significantly different between the groups. Likewise, 
many earlier studies have neither found differences (Table 1).   
In the schizophrenia group, higher cumulative lifetime antipsychotic doses associated with smaller 
volumes of total GM, cerebral GM, thalamus, and nucleus accumbens, and after adding PANSS 
total score to the model, the association in nucleus accumbens still remained, and the association in 
thalamus almost reached significance. Higher cumulative doses of benzodiazepines associated with 
smaller volumes of total brain after controlling for antipsychotic doses and onset age (i.e. illness 
duration), but the association did not remain when adjusted for PANSS total score instead of onset 
age. 
In the affective psychoses group, there were no associations between lifetime antipsychotic doses 
and volumes of brain structures. Surprisingly, higher lifetime doses of benzodiazepines were 
associated with larger volumes in total GM, cerebral GM and thalamus after controlling for 
antipsychotic dose and PANSS total score. There were no statistically significant associations 
between group × medication dose and brain volumes in interaction analyses. 
In the systematic reviews, the differences in brain structures between schizophrenia and affective 
psychoses are not clear, since there are both since there are both studies reporting differences and 
no differences. The differences are reported mainly in gray matter volumes and basal ganglia 
structures. There are no previous studies on the association between benzodiazepine use and brain 
structures in affective psychoses, and of the studies focusing on the association between 
antipsychotic use and brain structures, there were only two statistically significant findings. 
4.2 Antipsychotic use and brain volumes 
In previous studies of an overlapping NFBC1966 sample, a higher amount of antipsychotic 
medication predicted total brain volume loss and lateral ventricular volume increase (Veijola et al., 
2014), as well as periventricular brain volume reductions at the fourth ventricular edge (Guo et al., 
2015) over a 9-year follow-up. In addition to brain findings, in the NFBC1966, higher doses of 
antipsychotics associated with decline in verbal learning and memory (Husa et al., 2014), and high 
lifetime doses and antipsychotic polypharmacy associated with poorer outcomes in schizophrenia 
(Moilanen et al., 2016). These previous findings and the findings of this study are somewhat 
consistent and suggest that high-dose long-term antipsychotic medications may have some non-
profitable effects on the brain in schizophrenia.  
Our results regarding the association of antipsychotics and lower gray matter volumes in 
schizophrenia are in line with the previous review of Haijma et al. (2013). However, the findings 
regarding associations between antipsychotic doses and smaller volumes in thalamus and nucleus 
accumbens in schizophrenia have not been reported by previous reviews, but instead they have 
reported larger volumes of thalamus and basal ganglia (Navari and Dazzan 2009; Scherck and 
Falkai 2006; Smieskova et al., 2009).  
Though the associations between higher lifetime doses of antipsychotics and brain structures in 
schizophrenia were confounded by PANSS total score, the overall estimates of the models including 
PANSS, sex, and ICV and antipsychotic dose, sex, and ICV were of the same magnitude (see data 
supplement table 8). Therefore, it seems, that antipsychotics, benzodiazepines, age of illness onset 
or duration of illnes and severity of symptoms all may have an effect on brain structures.  
In this study we wanted to expand the focus of antipsychotic effects also to affective psychoses, in 
which we hypothesized, that the effect would be similar to that of schizophrenia. However, we 
failed to detect any associations related to antipsychotic medication in the affective psychoses 
group. This may be due to the fact that the individuals with affective psychoses in our sample had 
higher onset age (i.e. shorter duration of illness) and partly because of this, the duration of 
medication and lifetime antipsychotic doses were much lower than in the schizophrenia group.  
Based on our systematic review, several previous studies have not found associations between 
antipsychotics and brain morphology in affective psychoses (Table 2). The only positive findings 
were from studies by Liberg et al., 2015, where they found an association between antipsychotic 
medication and positive vertex displacement in the right pallidum in psychotic bipolar disorder, and 
Morgan et al., 2007, who found that longer duration of antipsychotic treatment was associated with 
an increased ventricular volume in the affective psychoses group. Though not many studies focus 
on affective psychoses and antipsychotic medications, there are studies on medication effects in 
affective disorders in general. A review on medication effects on neuroimaging findings in bipolar 
disorder concluded that the effects of psychotrophic medications such as lithium or antipsychotics 
are predominantly normalizing and do not seem to affect the differences observed in volumes, white 
matter tracts or BOLD signal between bipolar disorder patients and healthy controls (Hafeman et 
al., 2012).  
4.3 Benzodiazepine use and brain volumes 
There are no previous cross-sectional studies on the association between benzodiazepine doses or 
use and brain structures measured with MRI in psychoses. In previous computed tomography 
studies, benzodiazepine use has not been associated with brain volumes (Busto et al., 2000; Lader et 
al., 1984; Moodley et al., 1993; Perera et al., 1987), with the exception of an association between 
benzodiazepines and increased ventricle-to-brain ratio (Schmauss and Krieg 1987; Uhde and 
Kellner 1987). In our previous longitudinal study on NFBC1966 data including a partly overlapping 
sample, we found that higher benzodiazepine doses during the 9-year follow-up were associated 
with a decrease in volume of the caudate nucleus after controlling for antipsychotic doses and 
PANSS average score (Huhtaniska et al., 2017b). 
In this study, lifetime benzodiazepine doses did not associate with any brain structures in 
schizophrenia at the age of 43 years, when antipsychotic doses were taken into account. In this 
sample, individuals with schizophrenia had used much more antipsychotics (mean dose 20.1 
DDDy) than benzodiazepines (mean dose 9.1 DDDy), and thus it might be hard to distinguish the 
effect of these two medications. Also, in schizophrenia, the lifetime benzodiazepine doses may 
indicate a more severe illness (Takita et al., 2016), since polypharmacy including antipsychotics and 
benzodiazepines has been linked to poorer outcome (Längle et al., 2012).  
On the other hand, in the affective psychoses group, higher lifetime benzodiazepine doses 
associated with larger volumes in total gray matter, cerebral gray matter and thalamus even after 
controlling for antipsychotic dose and PANSS total score or onset age. In this group, the lifetime 
use of antipsychotics was lower (mean dose 4.7 DDDy) than lifetime use of benzodiazepines (mean 
dose 6.6 DDDy), which may partly explain this finding. It might even be, that in affective 
psychoses, benzodiazepine use with appropriate doses may help maintaining a better level of 
functioning after eliminating excess anxiety and hence associate with greater gray matter volumes. 
The practices for prescribing benzodiazepines might also be different in these two patient groups 
(Clark et al,. 2004).  
4.4 Strengths and limitations 
This study utilizes naturalistic birth cohort data, thus the sample is not selected and it may represent 
the clinical variability more realistically. In this natural setting it was possible to compare 
schizophrenia cases with cases with history of affective psychoses and to study both subgroups for 
association of lifetime antipsychotic or benzodiazepine doses with brain structure measurements at 
the age of 43 years. Our data is very heterogenous representing different stages of the disease 
including individuals in remission, more severely ill and with active psychosis.  
To our knowledge, there are no other studies with data on lifetime use of antipsychotics and 
benzodiazepines in individuals with schizophrenia or affective psychoses. The medication data has 
been collected very comprehensively by scrutinizing all available medical records and interviewing 
all subjects carefully at the time of the study.  
The main limitation of this study is the small sample size and the different number of cases in 
patient groups. Acknowledging the small sample size and the fact that we did not correct for 
multiple comparisons our findings may be by chance and the results must be considered 
exploratory. However, the findings regarding schizophrenia cases are in line with our previous 
longitudinal studies (Guo et al., 2015; Huhtaniska et al., 2017b; Veijola et al., 2014). 
The differences in background variables may also affect our results. The gender distribution was 
significantly different between the groups: in the affective psychoses 71% of the subjects were 
female vs. 39% in the schizophrenia group. In addition, the differences in marital status, age at 
illness onset, and severity of illness between the groups may affect the results.  There were also 
differences in the background variables between the groups that we could not control for in our 
analyses due to the lack of power. We had no data on symptom severity covering the whole illness, 
which could have provided a more reliable measure of illness severity.  
The cross-sectional design cannot answer the question whether there is an actual change in the brain 
structure volumes associated to medication, but unfortunately we do not have longitudinal data on 
brain changes in affective psychoses, though we have reported longitudinal findings in 
schizophrenia cases from this sample (Huhtaniska et al., 2017b). However, it could be presumed, 
that if these medications associate to brain structures in a longitudinal design, we would also detect 
associations when examining lifetime medication exposure in a cross sectional design. 
Though the medication data was collected very thoroughly, we cannot exclude the potential 
confounding effects of other psychotropic or somatic medications. Especially the use of lithium 
could confound the results, but since there had been only a few cases on lithium treatment during 
their whole lifetime and none at the time of the study, we did not find it relevant to include lithium 
use in our analyses. For the confounding effect of other mood stabilizers, we did not have the data. 
In addition, many individuals had used several different antipsychotics, and we could not study the 
effects of independent drugs.  
4.5. Conclusions 
At middle age (age of 43 years) there were no differences in brain structure volumes between 
schizophrenia and affective psychoses. There were many associations between larger lifetime doses 
of antipsychotics and lower volumes of brain structures in schizophrenia, but after adjusting for 
lifetime benzodiazepine doses, few of them remained. After additionally adjusting the analyses for 
PANSS total score only the association in nucleus accumbens remained. There were no associations 
between lifetime benzodiazepine doses and brain structures in schizophrenia after taking into 
account lifetime antipsychotic doses. In affective psychoses, there were no associations between 
lifetime antipsychotic doses and brain structures, but there was a positive association between 
lifetime benzodiazepine doses and total and cerebral gray matter and thalamus after controlling for 
antipsychotic dose and PANSS total score or onset age.  
Our findings underline the importance of taking benzodiazepine use and illness severity measures 
into account when studying antipsychotic effects on the brain. In addition, benzodiazepines and 
their effects on brain structures should be studied independently. More studies focusing on affective 
psychoses and medication effects are necessary. Further studies should also focus on how these 
findings correspond to cognition and functioning. 
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